AB Science SA
PAR:AB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
AB Science SA
Cash & Cash Equivalents
AB Science SA
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
AB Science SA
PAR:AB
|
Cash & Cash Equivalents
€5m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-12%
|
|
|
Sanofi SA
PAR:SAN
|
Cash & Cash Equivalents
€5.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Ipsen SA
PAR:IPN
|
Cash & Cash Equivalents
€1.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
19%
|
CAGR 10-Years
21%
|
|
|
Vetoquinol SA
PAR:VETO
|
Cash & Cash Equivalents
€171m
|
CAGR 3-Years
85%
|
CAGR 5-Years
16%
|
CAGR 10-Years
17%
|
|
|
Virbac SA
PAR:VIRP
|
Cash & Cash Equivalents
€122.5m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
9%
|
|
|
Medincell SA
PAR:MEDCL
|
Cash & Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
AB Science SA
Glance View
AB Science SA engages in the research, development, and sales of protein kinase inhibitor drugs. The company is headquartered in Paris, Ile-De-France and currently employs 96 full-time employees. The company went IPO on 2010-04-21. The company is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer, chronic inflammatory diseases, neurological degenerative disorders and central nervous systems diseases in both human and veterinary medicine. The main focus of the Company is the development of tyrosine kinase inhibitors, for instance Masitinib which is a tyrosine kinase inhibitor used as a veterinary medicine in the treatment of canine mast cell tumors. The firm is present in the United States and Europe. As of December 31, 2013, the Company operated though a subsidiary, AB Science USA LCC, based in the United States.
See Also
What is AB Science SA's Cash & Cash Equivalents?
Cash & Cash Equivalents
5m
EUR
Based on the financial report for Jun 30, 2025, AB Science SA's Cash & Cash Equivalents amounts to 5m EUR.
What is AB Science SA's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
-12%
Over the last year, the Cash & Cash Equivalents growth was -45%. The average annual Cash & Cash Equivalents growth rates for AB Science SA have been -13% over the past three years , -14% over the past five years , and -12% over the past ten years .
